GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study
Latest Information Update: 01 Sep 2023
At a glance
- Drugs Molgramostim (Primary)
- Indications Adult respiratory distress syndrome
- Focus Therapeutic Use
- Acronyms GI-HOPE
- 05 May 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified May 2021).
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 Oct 2021 Planned End Date changed from 31 Aug 2021 to 31 Jul 2022.